Skip to Main Content

AstraZeneca said Monday that its two immunotherapy cancer drugs, when combined with chemotherapy, slowed the progression of late-stage non-small cell lung cancer compared to chemotherapy alone.

The result comes just six days after Bristol-Myers Squibb reported similar findings with its own immunotherapy drugs and will likely lead to speculation as to whether Merck can hold onto its dominance in lung cancer with its treatment, Keytruda. Both data releases included only preliminary and incomplete data for investors, with full scientific results to follow in the future.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!